This category needs to be renamed to be meaningful than “Miscellaneous” but it will do for now. Basically it’s intended for news, research, legal actions and other information about medical marijuana for the general, nonexpert audience: patients, jouralists, the curious, etc.
Authored by Felecia Dawson, MD, ABOG and Genester Wilson-King, MD, FACOG Edited by Jahan Marcu, PhD In October 2025, the American College of Obstetricians and Gynecologists updated its guidance on…
FOR IMMEDIATE RELEASE National Clinical Director Consortium Announces Strategic Merger with the Society of Cannabis Clinicians to Advance Clinical Excellence in Medical Cannabis Care Denver, Colorado, March 20, 2026: The…
FOR IMMEDIATE RELEASE Society of Cannabis Clinicians Announces Partnership with Whole Health Oncology Institute to Advance Patient-Reported Outcomes in Medical Cannabis Care Los Angeles, CA — February 24, 2026 —…
Policy Statement on Hemp Regulation and Public Health Society of Cannabis Clinicians (SCC) The Society of Cannabis Clinicians (“SCC”) is committed to advancing scientific understanding, clinical practice, and responsible policy…
The Society of Cannabis Clinicians (SCC) proudly announces its newly elected Executive Committee, marking a historic milestone in the organization’s 26-year history. For the first time, SCC is led by…
Cannabis and the Heart: A Clinical Interpretation of the Evidence Authored by the SCC Media Response Committee The relationship between cannabis and its impact on cardiovascular health has attracted growing…
Cannabis and the Heart: Clinicians Weigh in on Risks and Realities A new meta-analysis raises questions—clinicians weigh in on what we really know about cannabis and cardiovascular events. By: Jahan…
Jun 12, 2025 By Elisabeth Mack, MBA, BSN, RN & Member of the SCC Media Response Committee When Adult-Use Eclipses Medical: How Recreational Cannabis Legalization Has Undermined Patient Care Cannabis…
View full article here. A data driven response to “Aspergillus in Cannabis: Evaluating the Evidence and Crafting Sensible Policies”. Kevin McKernan, Sherman Hom, Ben Amirault, Yvonne Helbert, Steve McLaughlin, Liam…
Non-prescription cannabidiol (CBD) and medical marijuana (cannabis) currently do not have US Food and Drug Administration (FDA)-approved prescribing information nor a dedicated resource to evaluate potential cannabinoid drug-drug interactions with other medications. The CANNabinoid Drug Interaction Review (CANN-DIR™) is a free web-based platform that has been developed to screen for potential drug-drug interactions from the perspective of how a cannabinoid delta-9-tetrahydrocannabinol (THC), CBD, or a combination of THC/CBD may affect the metabolism of another prescribed medication. CANN-DIR™ is based on FDA-approved prescribing information for the prescription cannabinoids (dronabinol, nabilone, nabiximols, and prescription CBD) and other FDA-approved prescribing information for medications sharing similar metabolic enzymes (e.g., the FDA “Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers”). The Summary of Product Characteristics (SmPC) was the source of drug-drug interaction information for the combined ∆9-THC & CBD product nabiximols (Sativex®). CANN-DIR™ provides an expeditious review of cannabinoid drug-drug interaction information, and also a platform from which the patient and health care provider can print out the search results to either initiate a conversation, or for the health care provider to provide a written information sheet to supplement their verbal discussion.
Cannabis has a historical role for pharmacological analgesia/anaesthesia, as well as for dental anxiety. Fast-forward to today’s scientific literature, there are many considerations regarding the role of cannabis in dentistry. We examine the role of the endocannabinoid system and its modulation from the dental perspective. Whilst cannabis smoking has been associated with poor dental health, and tetrahydrocannabinol (THC) intoxication can result in tachycardia and acute hypertension, (which could cause drug-drug interaction with sedation and anaesthesia), some cannabinoids seem to be useful for a promising therapy for a range of different conditions of the oral cavity, such as peri-operative analgesia, several neurologic orofacial disorders, like burning mouth syndrome, or even dental anxiety and mouth inflammations.